This fusion protein has a greatly improved PK profile (17–21 h half-life in mice versus 3–5 min for rhTRAIL), benefits from functional synergy between ADI and TRAIL, and has potent anti-cancer activities in vitro and in vivo (Figures 3–5). This evidence concerns the gene TNFSF10 and cancer.